[Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel]

Gan To Kagaku Ryoho. 2005 Dec;32(13):2097-9.
[Article in Japanese]

Abstract

Carcinomatous meningitis from breast cancer is rare and has a poor prognosis with a life expectancy of approximately 80 days. We performed intrathecal MTX and Ara-C in combination with systemic docetaxel treatments in the patient, a 44-year-old woman with carcinomatous meningitis from invasive lobular carcinoma previously treated with anthracycline and paclitaxel. Although the patient died 128 days after the onset, intrathecal chemotherapy in combination with systemic docetaxel reduced the number of malignant cells and induced degeneration of the cells in CSF, resulting in improved quality of life.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / pathology*
  • Carcinoma, Lobular / pathology*
  • Cerebrospinal Fluid / cytology
  • Cytarabine / administration & dosage
  • Docetaxel
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Spinal
  • Meningeal Neoplasms / cerebrospinal fluid
  • Meningeal Neoplasms / pathology*
  • Meningitis / cerebrospinal fluid
  • Meningitis / drug therapy*
  • Meningitis / etiology
  • Methotrexate / administration & dosage
  • Quality of Life*
  • Taxoids / administration & dosage

Substances

  • Taxoids
  • Cytarabine
  • Docetaxel
  • Methotrexate